Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $6.25, but opened at $5.92. Valneva shares last traded at $5.9410, with a volume of 4,551 shares.
Valneva Stock Performance
The firm has a market cap of $524.41 million, a PE ratio of -3.85 and a beta of 1.97. The company has a current ratio of 2.38, a quick ratio of 1.85 and a debt-to-equity ratio of 1.52. The firm's 50 day simple moving average is $9.34 and its 200 day simple moving average is $9.42.
Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings results on Sunday, February 15th. The company reported ($0.68) EPS for the quarter. The company had revenue of $55.92 million during the quarter. Valneva had a negative return on equity of 76.81% and a negative net margin of 67.64%. On average, research analysts forecast that Valneva SE Sponsored ADR will post 0.13 EPS for the current fiscal year.
Institutional Trading of Valneva
Hedge funds have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. purchased a new stake in shares of Valneva during the 2nd quarter valued at about $8,240,000. Marex Group plc purchased a new stake in shares of Valneva during the 2nd quarter valued at about $64,000. JPMorgan Chase & Co. purchased a new position in shares of Valneva during the third quarter worth approximately $124,000. VSM Wealth Advisory LLC increased its position in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company's stock worth $110,000 after acquiring an additional 5,000 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Valneva during the fourth quarter valued at approximately $44,000. Hedge funds and other institutional investors own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva's research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.
Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of ten stocks that are set to soar in 2026, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
